Correspondingly, among the identified drug hits were pan-CDK inhibitors flavopiridol and dinaciclib which are in early phase trials for neuroblastoma and advanced solid tumors (23–25), and mTOR ATP-competitive inhibitor INK128 (70.5% mean cytotoxicity) and PI3K inhibitor PIK-75, both with known preclinical activity against neuroblastoma (26, 27). This evidence concerns the gene MTOR and neuroblastoma.